Third Harmonic Bio
Third Harmonic Bio raises $200M Series C at $750M valuation
Quick Facts
Third Harmonic Bio: Series C Funding Round
Third Harmonic Bio has successfully raised $200M in Series C funding, reaching a valuation of $750M.
Company Overview
Dicerna-based RNAi therapeutics
Funding Details
The Series C round was led by ARCH Venture Partners, with participation from Polaris Partners, RA Capital Management, GV.
Company Information
- Headquarters: 325 Vassar Street, Cambridge, MA 02139
- Founded: 2019
- Employees: 100+
- Category: Biotech
Investment
Third Harmonic Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series C
- Polaris Partners: Verified investor in Series C
- RA Capital Management: Verified investor in Series C
- GV: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...